Shanghai Pharmaceuticals Holding Co. Ltd. has identified C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, cancer, systemic lupus erythematosus, rheumatoid arthritis and drug-induced rash.
Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Group Co. Ltd. have patented C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
Work at Shanghai Meiyue Biotech Development Co. Ltd. has led to the discovery of spiro-heterocycle substituted pyrimidine compounds acting as C-C chemokine receptor type 4 (CCR4) antagonists.
HONG KONG – Rapt Therapeutics Inc., of San Francisco, and Seoul, South Korea-based Hanmi Pharmaceutical Co. Ltd. entered a license agreement for Rapt’s FLX-475 in Asia. FLX-475 is an oral, small-molecule CCR4 antagonist for cancer treatment.
